SCHOTT PHARMA AG & CO. KGAA
SCHOTT PHARMA AG & CO. KGAA/ DE000A3ENQ51 /
1SXP
|
03/09/2024 15:30:42
|
Var.
-0.70
|
Volume |
Denaro17:04:00 |
Lettera17:04:00 |
Capitalizzazione di mercato |
Dividend Y. |
Rapporto P/E |
|
34.74EUR
|
-1.98%
|
0
Fatturato: - |
34.48Quantità in denaro: 258 |
34.56Quantità in lettera: 258 |
5.2 bill.EUR |
0.43% |
34.16 |
Descrizione business
For more than 100 years, the SCHOTT name has represented advanced solutions and services for the global pharmaceutical and biotech industries. With this longstanding expertise, SCHOTT Pharma provides an extensive and scientifically proven product portfolio for the safe storage and administration of injectable drugs to patients all over the world.
SCHOTT Pharma`s portfolio ranges from prefillable syringes, cartridges, vials, and ampoules to analytical, development, fill-and-finish, and regulatory services for pharmaceutical companies, biotechs, and CDMOs.
Consiglio di amministrazione & Consiglio di sorveglianza
| CEO |
| - |
| Consiglio di amministrazione |
| Andreas Reisse, Dr. Almuth Steinkuhler |
| Consiglio di sorveglianza |
| Peter Goldschmidt, Dr. Wolfgang Wienand, Ann-Kristin Erkens , Eva Kienle, Christine Wening, Mario Just, Dr. Jorg Flatten, Thomas Schoning, Oliver Spika, Kai Olbricht |
Dati aziendali
| Name: |
SCHOTT PHARMA INH O.N. |
| Indirizzo: |
Hattenbergstrasse 10,Mainz, 55122 |
| Telefono: |
- |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
https://www.schott-pharma.com/ |
| Industria: |
Healthcare |
| Settore: |
Medical Products |
| Sub settore: |
Medical Supplies |
| Fine dell'anno finanziario: |
30/09 |
| Flottante libero: |
23.00% |
| Data dell'IPO: |
28/09/2023 |
Rapporti con gli investitori
| Name: |
Jasko Terzic |
| IR telefono: |
- |
| IR Fax: |
- |
| IR e-mail: |
IR.Pharma@schott.com
|
Company calendar
|
CW 50 | 12/12/2024
Annual Report
|
|
CW 6 | 04/02/2025
General Shareholder Meeting
|
|
CW 7 | 13/02/2025
Interim Report 1st Quarter/3 Months
|
|
CW 20 | 15/05/2025
Interim Report 2nd Quarter/6 Months
|
|
CW 33 | 12/08/2025
Interim Report 3rd Quarter/9 Months
|
